Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Conditions
Metastatic Malignant Solid Neoplasm · Unresectable Malignant Solid Neoplasm
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Contact: Principal Investigator (Sharonlin Bhardwaj)UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
Contact: Principal Investigator (Shumei Kato)Los Angeles General Medical Center, Los Angeles, California, United States
Contact: Principal Investigator (Varsha Tulpule)USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Contact: Principal Investigator (Varsha Tulpule)UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
UC San Diego Medical Center - Hillcrest, San Diego, California, United States
Contact: Principal Investigator (Shumei Kato)University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Contact: Study coordinator (Site Public Contact) · cancerclinicaltrials@bsd.uchicago.edu · 773-702-8222Contact: Principal Investigator (Gini F. Fleming)National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
Contact: Principal Investigator (A P. Chen)National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Gerburg M. Wulf)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Geoffrey I. Shapiro)NYU Langone Hospital - Long Island, Mineola, New York, United States
Contact: Principal Investigator (Nancy Chan)Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Contact: Principal Investigator (Nancy Chan)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (John L. Hays)University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Contact: Principal Investigator (Debra L. Richardson)Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Contact: Principal Investigator (Vaia Florou)Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Principal Investigator (Michael Schweizer)University of Washington Medical Center - Montlake, Seattle, Washington, United States
Contact: Principal Investigator (Michael Schweizer)University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
Contact: Principal Investigator (Jeremy Kratz)University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
Contact: Principal Investigator (Jeremy Kratz)University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
Study leads
Geoffrey I Shapiro
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO